Kane Net Income From Continuing Ops from 2010 to 2026
| KNE Stock | CAD 0.04 0.00 0.00% |
Net Loss | First Reported 2016-12-31 | Previous Quarter -348.5 K | Current Value -607.3 K | Quarterly Volatility 568.1 K |
Check Kane Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kane Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 288.1 K, Total Revenue of 2.5 M or Gross Profit of 1.1 M, as well as many indicators such as Price To Sales Ratio of 7.73, Dividend Yield of 0.0 or Days Sales Outstanding of 16.88. Kane financial statements analysis is a perfect complement when working with Kane Biotech Valuation or Volatility modules.
Kane | Net Income From Continuing Ops |
The evolution of Net Income From Continuing Ops for Kane Biotech provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Kane Biotech compares to historical norms and industry peers.
Latest Kane Biotech's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Kane Biotech over the last few years. It is Kane Biotech's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kane Biotech's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Kane Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (2,628,234) | |
| Coefficient Of Variation | (45.08) | |
| Mean Deviation | 988,539 | |
| Median | (2,786,174) | |
| Standard Deviation | 1,184,799 | |
| Sample Variance | 1.4T | |
| Range | 3.9M | |
| R-Value | (0.70) | |
| Mean Square Error | 771.4B | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (163,368) | |
| Total Sum of Squares | 22.5T |
Kane Net Income From Continuing Ops History
About Kane Biotech Financial Statements
Kane Biotech investors use historical fundamental indicators, such as Kane Biotech's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kane Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -2.8 M | -3 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Kane Stock Analysis
When running Kane Biotech's price analysis, check to measure Kane Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kane Biotech is operating at the current time. Most of Kane Biotech's value examination focuses on studying past and present price action to predict the probability of Kane Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kane Biotech's price. Additionally, you may evaluate how the addition of Kane Biotech to your portfolios can decrease your overall portfolio volatility.